About this trial
This study aims to evaluate the impact of using propranolol, a non-selective beta-blocker, on preventing myocardial injury after non-cardiac surgery (MINS) in breast cancer patients who also have hypertension or angina. Stress from surgery and anesthesia can increase sympathetic activity and inflammation, which may lead to heart stress. This pragmatic clinical trial will compare patients who are prescribed propranolol as part of their routine care with those who are not. Researchers will analyze blood samples and surgical tissues collected during normal treatment to observe changes in heart health and the tumor microenvironment.
Eligibility criteria
Qualifiers
Female patients aged 20 to 70 years.
Patients diagnosed with hypertension or angina who require medication.
Patients diagnosed with unilateral, resectable primary breast cancer (ICD-10: C50), Stage I-III.
ECOG performance status of 0-1.
Disqualifiers
Patients with distant metastases.
Patients with active infectious diseases, autoimmune diseases (including specific rheumatic diseases), coagulation disorders, or cardiovascular diseases other than hypertension or angina pectoris.
Platelets <100,000/mm3
Hb <9 g/dL
Trial design
Treatments tested in this trial
- propranolol
- Usual Care
Treatment groups
Sponsors and collaborators
Chang-Ik Yoon
Lead sponsor
Seoul St. Mary's Hospital
Sponsor institution
Seoul St. Mary's Hospital
Collaborator